Institution profile

医療法人社団 青葉会 仙台駅前アエルクリニック

Explore the institution's name, address and registered technologies as published, along with plan classifications, score components and sources.

The ranking reflects only the registration data published by Japan's Ministry of Health, Labour and Welfare; it does not represent treatment outcomes or quality of care. Scoring method →

Source: Ministry of Health, Labour and Welfare public directory of regenerative medicine providers MHLW e-Regenerative Medicine public register · Directory archive date I: 2026-07-19 / II: 2026-09-26 / III: 2026-05-18 · Internet Archive

MHLW e-Regenerative Medicine public registerPublic document number 03B2509004 +5

Location

Prefecture
Miyagi
Address
仙台市青葉区中央1丁目3番1号 AERビル11階

Plan classification

  • Class INot registered
  • Class IINot registered
  • Class IIIThe low-risk category under the law.

Certified committee for regenerative medicine

  • 一般社団法人分子免疫学研究所認定再生医療等委員会
  • 一般社団法人 分子免疫学研究所 認定再生医療等委員会
  • 医療法人清悠会認定再生医療等委員会

Public score

35.9/ 100

A · Review level
10.0 / 30
B · Technologies
22.4 / 35
C · Coverage
3.6 / 25
D · Class I / II technologies
0.0 / 10

The public score is calculated from public registration information and does not reflect quality of care. Scoring method →

Overall ranking

No. 1407of 1736

Registered technologies
6
Areas covered
1

Technology areas · Rank

Position in the overall score distribution

0–100 · Public score
000–9.9 · 0 institutions
01010–19.9 · 0 institutions
2172020–29.9 · 217 institutions
3163030–39.9 · 316 institutions
7564040–49.9 · 756 institutions
2465050–59.9 · 246 institutions
1326060–69.9 · 132 institutions
417070–79.9 · 41 institutions
248080–89.9 · 24 institutions
49090–100 · 4 institutions
This institution 35.9
Public score →100

Registered technologies (6)

NK and immune cells 5
Registered technologies · Japanese originalTechnology areasPlan classification
悪性腫瘍に対する活性化リンパ球療法NK and immune cellsClass III
悪性腫瘍に対する高活性NK細胞輸液剤療法NK and immune cellsClass III
NKTがんワクチンGC-MO(α-Galactosylceramideパルスヒト自家CD14陽性細胞)を用いたiNKTがん免疫治療NK and immune cellsClass III
悪性腫瘍の予防および治療のための カルバメート糖脂質感作自己樹状細胞ワクチンによるNKT細胞標的治療NK and immune cellsClass III
悪性腫瘍の予防および治療のための樹状細胞ワクチン療法NK and immune cellsClass III
Other 1
Registered technologies · Japanese originalTechnology areasPlan classification
悪性腫瘍の予防および治療のための活性化末梢血単核球療法OtherClass III

Certified committee for regenerative medicine

  • 一般社団法人分子免疫学研究所認定再生医療等委員会
  • 一般社団法人 分子免疫学研究所 認定再生医療等委員会
  • 医療法人清悠会認定再生医療等委員会

Public document number

  • 03B2509004
  • 03B2509005
  • 03B2509007
  • 03B2509008
  • 03B2509006
  • 03B2509003
Plan classification · Certified committee for regenerative medicine · Public document number
Registered technologiesPlan classificationCertified committee for regenerative medicinePublic document number
悪性腫瘍に対する活性化リンパ球療法Class III一般社団法人分子免疫学研究所認定再生医療等委員会03B2509004
悪性腫瘍に対する高活性NK細胞輸液剤療法Class III一般社団法人分子免疫学研究所認定再生医療等委員会03B2509005
悪性腫瘍の予防および治療のための活性化末梢血単核球療法Class III一般社団法人 分子免疫学研究所 認定再生医療等委員会03B2509007
NKTがんワクチンGC-MO(α-Galactosylceramideパルスヒト自家CD14陽性細胞)を用いたiNKTがん免疫治療Class III医療法人清悠会認定再生医療等委員会03B2509008
悪性腫瘍の予防および治療のための カルバメート糖脂質感作自己樹状細胞ワクチンによるNKT細胞標的治療Class III一般社団法人分子免疫学研究所認定再生医療等委員会03B2509006
悪性腫瘍の予防および治療のための樹状細胞ワクチン療法Class III一般社団法人分子免疫学研究所認定再生医療等委員会03B2509003

Other institutions in the same prefecture

← Institution directory
One-to-one advice

Still unsure? Ask an advisor

Use the “Chat with an advisor” button on this page (at the bottom of the screen on mobile, bottom right on desktop) to open a chat with the Stem Cell Japan advice desk. Consultation and coordination are free, and an advisor replies within one working day.

Chat with an advisor